Adenovirus serotype 5 (Ad5) displays unparalleled gene transfer efficacy to cells with high coxsackie-adenovirus receptor (CAR) expression. Unfortunately, cells isolated from clinical human cancers, both ovarian and other types, express highly variable and often low levels of CAR. Fortunately, native Ad5 tropism can be modified to circumvent CAR deficiency and to enhance infectivity. Ad5/3luc1 incorporates the serotype 3 fiber knob and binds to a receptor distinct from CAR, while the fiber of Ad5lucRGD is modified with an RGD-4C motif, allowing CAR-independent binding to integrins. We studied the liver tropism and blood clearance of these viruses after intravenous (i.v.) injection, and biodistribution after intraperitoneal (i.p.) injection to tumor-bearing mice. To estimate efficacy, we assessed gene transfer to purified human primary ovarian cancer cells, and in a mouse model of ovarian cancer. Ad5/3luc1 achieved improved gene transfer over Ad5lucRGD, and both infectivity-enhanced viruses were superior to the isogenic control with an unmodified Ad5 capsid. In the presence of malignant ascites, gene transfer was improved with both Ad5/3luc1 and Ad5lucRGD. Thus, retargeting to the Ad3 receptor enhances gene transfer to clinically relevant ovarian cancer substrates, while the mouse toxicity and biodistribution profile of both fiber-modified Ad vectors is comparable to Ad5.
INTRODUCTION
The adenovirus (Ad) is a useful cancer gene therapy vector, because it infects both proliferating and quiescent cells and its immunogenicity may help to evoke an immune response toward potentially remaining tumor cells [1] . Most importantly, > 700 cancer patients have received Ad intratumorally, intraarterially, intraperitoneally, and intravenously in clinical trials, with few severe side effects and generally mild toxicity [2, 3] . Entry of Ad into cells initiates with binding of the fiber knob to the primary receptor, which is the coxsackie-adenovirus receptor (CAR) for most serotypes, including the ubiquitously used serotype 5 (Ad5) [1] . Binding is followed by interaction of the Ad penton base with cellular ␣ v ␤ group integrins, which leads to internalization. Recent data suggest that binding is the rate-limiting step [4] [5] [6] [7] [8] [9] . Thus, although Ad has a number of characteristics that make it an appealing agent for the treatment of cancer, lack of the primary receptor could make target tissues refractory.
Most ovarian cancer patients have peritoneally disseminated disease, which is associated with a dismal prognosis. However, the compartmentalized nature of the disease creates a rationale for local treatment. Intraperitoneally administered gene therapy with Ad has been attempted in several trials [10] [11] [12] [13] . Importantly, the safety data have been excellent, with doses as high as 7.5 ϫ 10 13 viral particles (VP)/day administered for 5 consecutive days, without dose-limiting toxicity [12] . In contrast, gene transfer data have been minimal, and there is little evidence supporting a potential clinical benefit.
The reason for the low gene transfer efficacy to clinical tumors is becoming increasingly clear, because there is mounting evidence that tumor cells extracted from human ovarian cancer patient samples express highly variable and often low amounts of CAR [14] [15] [16] [17] [18] . This phenomenon is not restricted to ovarian cancer and could be a general phenomenon associated with malignant progression [4, 5, 7, 19, 20] . In contrast, CAR is expressed ubiquitously on ARTICLE doi:10.1006/mthe.2002.0599, available online at http://www.idealibrary.com on IDEAL alternate Ad serotype [15, [30] [31] [32] . Specifically, Ad3 has a distinct but unidentified receptor [33] . In addition, our previous studies suggest that the Ad3 receptor is expressed at higher levels than CAR on ovarian cancer cells and that 5/3 serotype chimeras bind to the Ad3 receptor but not to CAR [15] . It is conceivable that the Ad3 receptor, as opposed to CAR, may not be involved in the carcinogenic process and thus not downregulated in advanced tumors [15] .
In this study, we compared two fiber-modified Ad vectors, Ad5lucRGD and Ad5/3luc1, to the isogenic control with a wild-type Ad5 capsid (Ad5luc1). Ad5lucRGD incorporates an RGD-4C motif, and Ad5/3luc1 is a serotype chimera with the knob domain from serotype 3. Our results suggest that in mice, the toxicity, blood clearance, and biodistribution profile of the fiber-modified Ad vectors is comparable to Ad5. Furthermore, retargeting to the Ad3 receptor dramatically enhances transduction of primary human ovarian cancer cells. The advantage of the fiber modifications became even more obvious in the presence of malignant ascites. Finally, Ad5/3luc1 achieved improved transgene expression in an animal model of ovarian cancer. most normal epithelial tissues [21] . Thus, without retargeting, low CAR expression on tumor cells may cause low gene transfer efficiency to cancer cells, but high transduction and consequent toxicity to nonmalignant cells. The function of CAR is not well understood, but it may be associated with adhesion and tight junctions [22] [23] [24] . It has been suggested that CAR levels correlate inversely with the aggressiveness of the tumor and that the presence of CAR causes a tumor-suppressing effect [23] .
Fortunately, Ad can be directed to receptors not downregulated in cancers. The concept has been validated by incorporation of an arginineglycine-aspartic acid (RGD-4C) modification into the HI loop of the fiber [14] . RGD-4C is closely related to the penton base RGD motif, which mediates Ad internalization [25] . RGD motifs are present in a number of cell adhesion molecules, including fibronectin and vitronectin, and are thus not completely foreign to humans, which could be important from a safety standpoint. RGD-4C allows binding to the ␣ v ␤-integrins, which are regularly expressed and often overexpressed on ovarian cancer cells [26] and tumor vasculature [27] . RGD-4C-modified adenoviruses have been shown to achieve infectivity enhancement to low-CAR targets, including ovarian cancer [7, 17, 20, 26] . Also, a proposal for a human ovarian cancer clinical trial with an RGD-4C-modified Ad has been presented to the National Institutes of Health Recombinant DNA Advisory Committee with a positive response [28] . An additional advantage of targeting could be reduced neutralization by preexisting neutralizing anti-adenovirus antibodies [26, 29] .
True genetic retargeting can be achieved by substitution of the knob domain of Ad5 with a knob from an FIG. 1. Liver toxicity and blood clearance are not significantly affected by tropism modification of the adenovirus fiber. Immune-competent mice were injected through the tail vein with 5 ϫ 10 10 VP of Ad5luc1, Ad5/3luc1, Ad5lucRGD, or no virus. Serum transaminases were measured at 72 hours; error bars indicate standard deviation (A, B). Histopathology was analyzed following formalin fixation and hematoxylin and eosin staining 72 hours after i.v. injection of Ad5luc1 (C), Ad5/3luc1 (D), or Ad5lucRGD (E). Sections of the livers were used for analysis of transgene expression (F). Bar, median, *P < 0.05 versus Ad5luc1. Blood clearance after injection of 5 ϫ 10 10 VP of the viruses was determined at the indicated time points (G). All infections were done in triplicate. 
RESULTS

Liver Toxicity and Blood Clearance Rates of Fiber Knob-Modified Adenoviruses
To assess liver toxicity, 5 ϫ 10 10 VP were injected intravenously (i.v.) into immune-competent mice. After 72 hours, serum asparate aminotransferase (AST) (Fig. 1A ) and alanine aminotransferase (ALT) (Fig. 1B ) levels were measured. All viruses caused moderate release of transaminases, with readings threefold higher than without virus. There were no significant differences between the groups.
To evaluate toxicity further, livers were harvested and analyzed histopathologically. Generally, the changes were mild to moderate, and the group injected with Ad5/3luc1 showed less cytomorphologic hepatic changes than those receiving the other viruses (Table 1 ). In the Ad5luc1 group, mild abnormalities were found, a few portal triads displayed mild chronic inflammation, some vascular leakage, and mild scattered hepatocyte drop-out and necrosis within the parenchyma (Fig. 1C) . Ad5/3luc1 caused only minimal changes, rare portal triad chronic inflammation, mild scattered parenchymal inflammation, and focal hepatocyte necrosis (Fig. 1D ). Mice injected with Ad5lucRGD had focal hepatocyte necrosis, congestion, and moderate portal triad chronic inflammation, but no parenchymal inflammation (Fig. 1E) .
Transgene expression was lower in the livers injected with fiber-modified viruses in comparison to Ad5luc1 (Fig.  1F) . The difference between Ad5lucRGD and Ad5luc1 was statistically significant (P = 0.0404). We analyzed blood clearance rates by collecting plasma samples 1-60 minutes after i.v. virus injection. The blood clearance curves for the viruses were similar and showed rapid decrease of the viruses in the blood (Fig. 1G) .
Biodistribution of Adenoviral Vectors with Fiber Knob Modifications Following Intraperitoneal Administration to Tumor-Bearing Mice
Biodistribution was assessed after intraperitoneal (i.p.) injection of viruses, as would be offered in human ovarian cancer gene therapy trials. At 48 hours, liver, spleen, kidneys, heart, lungs, peritoneum, brain, and ovaries were harvested, and luciferase activity and protein concentration of tissue lysates were measured. Also, blood samples were collected and blood cells separated and analyzed. Highest transgene expression was seen in the spleen, ovaries, peritoneum, and liver ( Fig. 2A) . In the liver, the luciferase activity was significantly higher with Ad5/3luc1 in comparison with Ad5luc1 (P = 0.0472). Ad5lucRGD displayed enhanced transgene expression in heart tissue (versus Ad5luc1 and versus Ad5/3luc1, P = 0.0335 for both) and in the lungs (versus Ad5luc1, P = 0.0472). Ad5/3luc1 demonstrated reduced transgene expression in the peritoneum (versus Ad5luc1 and versus Ad5lucRGD, P = 0.0335 for both). In the brain, the transgene expression was significantly higher with Ad5luc1 (versus Ad5/3luc1, P = 0.0335; versus Ad5lucRGD, P = 0.0472). And finally, Ad5/3luc1 displayed reduced infectivity in blood cells (versus Ad5luc1, P = 0.0472; versus Ad5lucRGD, P = 0.0335).
Other differences were not statistically significant.
To estimate the total virus uptake by each organ, uninfected mice were killed, after which the total protein content of each organ was determined and total luciferase activity per organ was calculated. The liver had the highest total transgene expression, followed by the spleen, kidneys, and ovaries ( Fig. 2B) . Because peritoneum and blood are difficult to collect completely, organ normalization was not done.
Finally, we carried out quantitative PCR to study the liver transduction of the vectors (Fig. 2C) . Infection with Ad5luc1 resulted in a median of 139,000 copies/ng DNA versus 43,000 and 26,000 with Ad5/3luc1 and Ad5lucRGD, respectively (P = 0.0335 for both).
Infectivity of Human Mesothelial Cells in Vitro
Human embryonal kidney cells ( Figs. 3B-3F). In most cases, Ad5lucRGD also enhanced infectivity of mesothelial cells in vitro. With 1000 VP/cell, transgene expression was 0.7-to 44-fold higher compared with Ad5luc1. Other amounts of viruses gave similar results. The 293 cells can easily be infected with all of these Ads [14, 15] ; this allows normalization for infectivity and thus an internal control for promoter and gene activity. The nearly identical luciferase activities with the three viruses ( Fig. 3A ) functionally demonstrates their isogenic structure and suggests that the difference seen with other cell types is due to differences in infectivity.
Infectivity of Purified Human Primary Ovarian Cancer Cells in Vitro
Five primary ovarian cancer samples were purified [34] to remove contaminating normal cells and then infected without passaging (Fig. 4) . Infection with 1000 VP/cell of Ad5/3luc1 resulted in 4.9-to 52-fold higher transgene expression in comparison with Ad5luc1 (Table 2) . Ad5lucRGD achieved 0.9-to 36-fold higher luciferase expression in comparison with Ad5luc1. With all five primary samples, infection with Ad5/3luc1 resulted in higher transgene expression than Ad5lucRGD.
Efficient Gene Transfer by Knob-Modified Adenoviruses in the Presence of Ascites
Viruses were preincubated with 1:10 or 1:100 dilutions of malignant ascites from ovarian cancer patients, and monolayers of SKOV3.ip1 (Figs. 5A and 5B) and OV-4 (Figs. 5C and 5D) were infected with 1000 VP/cell. Without ascites, infection with Ad5/3luc1 resulted in 61-to 84-fold higher transgene expression in comparison with Ad5luc1, but as much as 26,124-fold higher in the presence of ascites (Table  3) . Ad5lucRGD achieved 29-to 35-fold higher luciferase expression in comparison to Ad5luc1, but the ratio increased up to 637,208-fold in the presence of ascites.
Infectivity Enhanced Adenoviruses in an Animal Model of Ovarian Cancer
To evaluate the efficiency of tumor cell transduction in the context of in vivo gene delivery, Ad5luc1, Ad5/3luc1, or Ad5lucRGD were injected into established subcutaneous (s.c.) ovarian adenocarcinoma tumors (Fig. 6 ). Both fiber-modified vectors demonstrated significantly enhanced transgene expression in comparison with Ad5luc1 (versus Ad5/3luc1, P = 0.0064; versus Ad5lucRGD, P = 0.0014). Ad5/3luc1 resulted in higher transgene expression than Ad5lucRGD. 
DISCUSSION
Variable expression of CAR on human primary cancer cells is a major limitation of cancer gene therapy with Ad5. In contrast, many normal epithelial cells express CAR, and thus untargeted Ad5 may result in high transduction of nontarget tissues. The purpose of this study was to evaluate two tropism-modified viruses, Ad5lucRGD and Ad5/3luc1, for their capacity to improve transduction of the most stringent available preclinical ovarian cancer substrates. Also, to obtain preclinical safety data, we analyzed biodistribution, liver toxicity, and blood clearance. In mice, the liver is the major organ responsible for Ad clearance [35] [36] [37] and could therefore be an important organ in regard to potential clinical toxicity in humans. Kupffer cells have an important role in clearing Ad from the blood, but their uptake can be saturated, leading to a nonlinear dose effect at ~ 2 ϫ 10 10 VP in mice [37] . Only after saturation is achieved are hepatocytes and other tissues transduced effectively [37] . To evaluate immediately and early liver toxicity, we injected 5 ϫ 10 10 VP i.v. and analyzed serum transaminases, liver histopathology, and transgene expression at 72 hours (Fig. 1) . In general, only minor differences were seen, suggesting that the toxicity of tropism-modified viruses does not significantly differ from Ad5. Ad5 has been administered intravenously, intraperitoneally, intraarterially, and intratumorally in large doses in clinical trials without significant toxicity [3] . Thus, toxicity similar to Ad5 could predict a good safety profile for these tropism-modified viruses. Histopathologic analysis resulted in fewer findings with Ad5/3luc1 ( Table 1) . Transgene expression in the livers was slightly lower after injection with Ad5lucRGD and Ad5/3luc1 in comparison with Ad5luc1 (P = 0.0472 and not significant, respectively), which probably reflects differences in functional titer.
Viruses and other foreign particles in the blood are cleared mostly by Kupffer cells. Furthermore, the blood clearance of Ad is effective, with a half-life of < 2 minutes after a single i.v. injection [38] . We compared the blood clearance rates of the fiber-modified viruses to Ad5luc1 (Fig. 1G ) and found no differences. The clearance rate of Ad5luc1 was similar to what has been reported before [38] .
To obtain preclinical data on the biodistribution of the fiber-modified viruses in the context of i.p. administration, we conducted i.p. injection into tumor-bearing mice. When transgene expression was normalized for the amount of tissue analyzed, the highest transgene expression was seen in the spleen, ovaries, peritoneum, and liver ( Fig. 2A) . In the liver, luciferase activity was higher with Ad5/3luc1 in comparison with Ad5luc1, but the opposite was true after i.v. injection (Fig. 1F) . This probably resulted from the lower peritoneal uptake of Ad5/3luc1, subsequently allowing increased passage of Ad5/3luc1 into the blood and eventually into the liver. We estimated the total uptake of virus by organ, and the liver had the highest total transgene expression, followed by spleen, kidneys, and ovaries (Fig. 2B) . These results are in accord with previous reports describing liver as the main organ expressing transgene in mice after Ad injection [39, 40] .
Quantitative PCR was carried out to detect virus copies in the liver (Fig. 2C) . In contrast to the transgene expression data, fewer copies of Ad5/3luc1 were detected in the liver in comparison with Ad5luc1. These findings could reflect differences in uptake by Kupffer cells versus hepatocyte transduction. Kupffer cells are generally thought to be ineffective in transgene expression [37, 41] , although not all reports agree [42] . Thus, if Ad5luc1 has higher relative tropism for Kupffer cells in comparison with Ad5/3luc1, the result could be less transgene expression but higher copy number. This is supported by the higher liver toxicity seen with Ad5luc1 (Fig. 1C) . Kupffer cells are the main cells mediating immunologic responses in the liver [36, 41] , and less uptake could result in less inflammation. Clearly, this needs to be investigated in more detail in animals and, more importantly, in humans. Variables contributing to the findings could include capsid-dependent differences during post-entry steps. It is not well understood how Ad induces endosomal lysis and transport of its DNA to the nucleus, but it seems likely that the fiber plays a role. Conceivably, the rate of degradation of Ad by innate immune mechanisms could also be affected.
All ovarian cancer gene therapy trials published so far have relied on i.p. administration of the agent. Thus, the normal tissue that is in most immediate contact with the agent is the peritoneal lining. We analyzed the infectivity of two human established mesothelial cell lines and three fresh primary peritoneum samples (Fig. 3) . In contrast to the mouse in vivo data ( Figs. 2A and 2B) , the human mesothelial substrates displayed mostly increased infectivity with Ad5/3luc1 and, in some cases, also with Ad5lucRGD. For CAR, it has been shown that the localization of the receptor in the context of the three-dimensional structure is crucial in determining transduction [43] . Ratio of luciferase activity expressed as relative light units normalized for total protein concentration. Background luciferase activity was subtracted and values ≤ 0 were set as 1.
FIG. 6.
Retargeting adenovirus to the serotype 3 receptor (Ad5/3luc1) results in increased transgene expression in a human ovarian cancer xenograft model, when compared with infectivity enhancement with RGD-4C (Ad5lucRGD) or Ad5luc1 (wild-type fiber). Subcutaneous Hey cell tumors were established in nude mice followed by intratumoral injection of 2.5 ϫ 10 9 VP/nodule on 2 consecutive days. On the third day, tumors were harvested, and the luciferase activity was analyzed. Results are presented as relative light units (RLU) normalized for protein concentration, with each point representing an individual tumor. Bar, median; **P < 0.01 versus Ad5luc1. The situation could be similar for the receptor of serotype 3. In the intact peritoneum, the receptor may not be accessible and thus infectivity is low ( Figs. 2A and 2B) , whereas with the isolated cells, the receptor could be exposed. Alternatively, the process of enzymatic disaggregation of the mesothelial cells and initiation of culture could reduce the expression of CAR, and therefore increase the relative transgene expression mediated by the fiber-modified viruses. Finally, it is possible that human and mouse mesothelial cells display different expression patterns of the Ad3 receptor and/or CAR. In any case, it is unclear if transduction of the peritoneum is likely to cause severe side effects to patients. In the ovarian cancer trials published thus far, doses of up to 7.5 ϫ 10 13 VP of untargeted virus have been administered, and although abdominal pain was reported regularly, it was not dose-limiting [12] .
An important recent revelation has been that primary tumor cells express highly variable and often low amounts of CAR [4, 5, 7, [14] [15] [16] [17] [18] [19] [20] . Thus, it is crucial to analyze the most stringent available clinical substrates for reliable preclinical estimation of efficacy. For this purpose, we have developed a purification method that typically yields a > 95% pure population of cancer cells [34] . We analyzed the purified primary cells without passaging, which could help avoid confounding due to genotypic and phenotypic changes involved in the clonal selection process. In this case, five patient samples were infected (Fig. 4) . In comparison with Ad5luc1, transgene expression increased 0.9-to 36-fold when samples were infected with Ad5lucRGD. This is in accord with previous reports that have demonstrated that the RGD-4C modification increases the infectivity of primary ovarian cancer cells [14, 17, 26] . However, it should be noted that the actual level of infectivity enhancement conferred by the RGD-4C motif can only be demonstrated when the comparison is between isogenic viruses, that is, viruses containing identical expression cassettes, as were used in this case and in one other study [26] . Ad5/3luc1 achieved 5-to 50-fold higher transgene expression in comparison to Ad5luc1 (Fig. 4) , and in all cases, Ad5/3luc was superior to Ad5lucRGD (Table 2) . In an animal model of ovarian cancer, infection with Ad5/3luc1 and Ad5lucRGD resulted in higher transgene expression than with Ad5luc1. Xenografts contain variable amounts of host stromal cells, whose receptor expression levels influence the infectivity of the xenograft as a whole. This and the high local concentration of virus may have contributed to the relatively good infectivity seen with Ad5luc1. These results indicate that modification of the Ad5 fiber with an RGD-4C motif in the HI loop or swapping the knob for a serotype 3 knob can lead to significant enhancements in transduction of purified primary ovarian cancer cells and in vivo. Also, because the 5/3 chimera was superior to the RGD-4C, it is the best available genetic retargeting moiety for ovarian cancer. Our previous data suggest that transgene expression correlates closely with binding and transduction as opposed to possible downstream effects [15] .
At diagnosis, most ovarian cancer patients have ascites fluid. Previous studies have suggested partial escape of RGD-4C-modified viruses from neutralizing anti-adenovirus antibodies present in malignant ascites [26, 29] . Here, we have shown that Ad5/3luc1 is also able to circumvent neutralization (Fig. 5 and Table 3 ). In fact, in the presence of ascites, gene transfer was improved > 3 orders of magnitude in comparison with Ad5luc1. The level of neutralizing anti-Ad3 antibodies in ascites is unknown, but the prevalence of total serum anti-Ad3 antibodies seems to be comparable to that of anti-Ad5 [44] . However, in parallel to what has been suggested for RGD-4C-modified Ads [26, 29] , the chimeric nature of the Ad5/3luc1 fiber may allow escape from many of the anti-Ad3-fiber neutralizing antibodies, as such antibodies are often conformation-sensitive [45] .
In conclusion, we have shown that the mouse biodistribution, liver toxicity, and blood clearance of Ad5/3luc1 and of Ad5lucRGD are not significantly different from those of Ad5luc1. Both Ad5/3luc1 and Ad5lucRGD increased transgene expression in the most stringent available preclinical substrates, purified primary cancer cells, in the presence of neutralizing antibodies and in an animal model. These approaches could be useful for increasing transduction in the context of mutation compensation, delivery of genes coding for prodrug converting enzymes (molecular chemotherapy), or conditionally replicating viruses. Conditionally replicating viruses have recently shown promise in clinical trials [3] , albeit the most impressive result is in combination with chemotherapy [46] . Importantly, it has been clearly demonstrated that the oncolytic potency of replicating agents is directly determined by the capability of infecting target cells [47] . Thus, infectivity enhancement, such as described here, could help achieve higher clinical efficacy. Progress in clinical gene therapy of other diseases, such as cardiovascular disease, hemophilia, and severe combined immunodeficiency syndrome has been dependent on improvements in the vectors [48] [49] [50] . Clinical trials will ultimately show if preclinical advances such as reported here can help achieve similar progress in the field of ovarian cancer gene therapy. Fresh malignant ascites fluid samples from patients with pathologically confirmed ovarian adenocarcinoma were obtained from the University of Alabama at Birmingham (UAB) Hospital. Cancer cells were purified by a previously described immunomagnetic-based method [34] . Briefly, ovarian cancer cells were initially bound with a mouse anti-TAG-72-antibody, and then collected with magnetic beads coated with anti-mouse-IgG. Primary mesothelial cells were obtained by the enzymatic disaggregation of fresh peritoneal strips collected from female patients undergoing intraabdominal surgery with a strategy modified from previous reports [51] . The peritoneum strips were washed several times with PBS, and excess adipose tissue was removed. The sample was incubated with 15 ml of a solution containing 0.125% (wt/vol) trypsin (Mediatech, Herndon, VA), 0.01% (wt/vol) EDTA (Fisher Scientific, Fair Lawn, NJ), and 0.1% glucose (Sigma, St Louis, MO) for 20 minutes at 37°C on a rocker. Then, the suspension was centrifuged at 50g for 5 minutes at 4ЊC. The supernatant was discarded, and the cell pellet was washed once with 5 ml of Ham's F-12 supplemented with 10% FBS, 2 mM L-glutamine, penicillin (100 IU/ml), streptomycin (100 l/ml), and 10 ng/ml of recombinant human epidermal growth factor (EGF) (Life Technologies, Grand Island, NY). The pellet was resuspended in the same medium, and seeded in a 25-cm 2 tissue culture flask. Half of the medium was changed 24 hours later, and thereafter fully replaced once every 3 days. Cells were cultured without EGF at least 48 hours before infection to induce quiescence. For each sample, the cell type and purity was confirmed by immunohistochemistry (monoclonal antibodies recognizing calretinin, cytokeratin 5/6, and vimentin). To exclude tumor-contaminated mesothelial samples, H&E-stained sections of each piece of peritoneum were reviewed by a pathologist.
MATERIALS AND METHODS
Cells
Recombinant adenoviruses. The replication-incompetent Ad vectors have been described previously. Ad5luc1 [15] , Ad5/3luc1 [15] , and Ad5lucRGD [14] were propagated on 293 cells and purified on cesium chloride gradients. The viral particle (VP) concentration was determined at 260 nm, and standard plaque assay on 293 cells was done to determine infectious particles. The ratios of VP:infectious particles were 5.24, 45.7, and 51.1 for Ad5luc1, Ad5/3luc1, and Ad5lucRGD, respectively.
Ad-mediated gene transfer assays. Cells were infected for 30 minutes at room temperature at 50, 200, 1000, and 5000 VP/cell by adding Ad5luc1, Ad5/3luc1, or Ad5RGDluc1 diluted in 200 l of growth medium with 2% FBS. Cells were washed once, and complete medium was added. After 24 hours of incubation at 37ЊC, luciferase assay was done (Luciferase Assay System, Promega, Madison, WI). The protein concentration was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA) to allow normalization of the gene expression data for the number of cells. Background luciferase activities were subtracted from the readings.
For the results shown in Figure 5 , viruses were preincubated for 10 minutes at room temperature with malignant ascites fluid diluted 1:10 or 1:100 in growth medium with 2% FBS. Then, cells were infected at 1000 VP/cell for 1 hour at 37ЊC, followed by incubation and luciferase assay as before.
Animals.
Mice were obtained at 4-6 weeks of age and quarantined for at least 1 week before the study. Mice were kept under pathogen-free conditions according to the American Association for Accreditation of Laboratory Animal Care guidelines. Animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee of UAB.
In vivo liver toxicity. Female C57BL/6 mice (Charles River Laboratories, Wilmington, MA; n = 6/virus, n = 5/Opti-MEM), aged 8-10 weeks, were injected i.v. through the lateral tail vein with 5 ϫ 10 10 VP of Ad5luc1, Ad5/3luc1, or Ad5lucRGD in a volume of 300 l of Opti-MEM, or Opti-MEM only. After 3 days, small aliquots of blood (50 l) were collected from the tail vein and allowed to clot. Serum samples were separated by centrifugation, and transaminases were analyzed using GO-& GPTransaminase Kit 505 (Sigma). Then the mice were killed and pieces of the livers fixed in 10% neutral buffered formalin. Serial paraffin-embedded sections were taken and stained with H&E. Histopathology was scored blinded by two independent pathologists. A second liver sample was snap-frozen, and ground to a fine powder using a mortar and pestle cooled in a dry ice-ethanol bath. Liver powders were lysed using Cell Culture Lysis Buffer (Promega) at room temperature for 20 minutes. Lysates were frozen once, then centrifuged at 10,000g for 15 minutes. Luciferase activity and protein content in the supernatant was measured as before. Mean background luciferase activity was subtracted from the data. Clotting was prevented with heparin, and bleeding between intervals was suppressed with pressure. Samples were briefly centrifuged to separate the plasma. Aliquots of 1 l were used for triplicate infections of 293 cells, seeded in 96-well plates on the day before at 15,000 cells/well in 100 l of growth medium with 5% FBS. After 36 hours of incubation, luciferase activity was measured as before.
Biodistribution. To study biodistribution, we injected 6-week-old CB17 SCID mice (UAB Center for AIDS Research, CFAR SCID Mouse Core Facility; n = 5/group) i.p. with 1 ϫ 10 7 SKOV3.ip1 cells. After 10 days, 5 ϫ 10 10 VP of Ad5luc1, Ad5/3luc1, Ad5lucRGD, or no virus were injected i.p. in 1 ml of Opti-MEM. After 48 hours, blood samples were collected by cardiac puncture, blood cells were separated immediately by centrifugation, and the pellet was frozen. Organs were harvested and representative sections were snap-frozen. Transgene expression was analyzed as before. Mean background luciferase activity was subtracted from data. To be able to express results also as total RLU/organ, the total amount of protein in the organs of three uninjected mice was determined.
To quantitate the E4 copy number, liver DNA was purified using a DNeasy Tissue Kit (Qiagen, Valencia, CA). The primers used for amplifying the E4 gene were: forward (5Ј-GGAGTGCGCCGAGACAAC-3Ј), and reverse (5Ј-ACTACGTCCGGCGTTCCAT-3Ј), and the probe (5Ј-TGGCAT-GACACTACGACCAACACGATCT-3Ј). The mouse ␤-actin (an endogenous control) gene was amplified with primers: forward (5Ј-CGAGCGGTTCC-GATGC-3Ј), and reverse (5Ј-TGGATGCCACAGGATTCCAT-3Ј), and detected with a probe (5Ј-AGGCTCTTTTCCAGCCTTCCTTCTTGG-3Ј). The PCR conditions were as described earlier [26] . For deduction of the actual copy number, the sample fluorescence readings were compared with the standard curve created by amplifying known amounts of DNA (10 7 Hey cells into both flanks of 6-week-old female athymic CD-1 nude mice (Charles River Laboratories; n = 5/group). When the nodules reached 5 mm diameter, 2.5 ϫ 10 9 VP/nodule of Ad5luc1, Ad5/3luc1, or Ad5RGDluc1, or no virus, were injected intratumorally in a 30-l volume of Opti-MEM on 2 consecutive days (days 1 and 2), the total dose being 5 ϫ 10 9 VP/nodule. On the third day, the mice were killed, and the tumors harvested and snap-frozen. The tumors were ground, and luciferase activity analyzed as before. Mean background luciferase activity was subtracted from data.
Statistics. Statistical differences among groups were assessed with the Kruskal-Wallis test. When significant differences were detected, pairwise comparisons between groups were done with the Wilcoxon two-sample test.
